endpts.com Open in urlscan Pro
65.9.95.97  Public Scan

Form analysis
1 forms found in the DOM

https://endpts.com/

<form action="https://endpts.com/">
  <input type="text" name="s" placeholder="Search">
  <button class="epn_ux_button epn_white epn_search_submit_button"></button>
</form>

Text Content

 * Channels
   * All News
   * In Focus
   * Special
   * AI
   * Bioregnum
   * Biotech Voices
   * Cell/Gene Tx
   * China
   * Coronavirus
   * Deals
   * Diagnostics
   * Discovery
   * FDA+
   * Financing
   * Health Tech
   * Law
   * Letters to the Editor
   * Manufacturing
   * Marketing
   * Opinion
   * Outsourcing
   * Peer Review
   * People
   * Pharma
   * R&D
   * Startups
   * Weekly
 * Webinars
 * Biopharma Jobs
 * More
   * Work at Endpoints
   * Letter to Editors
   * IPO Tracker
   * Webinars
   * Events
   * Sponsored Posts
   * Advertise
   * Privacy Policy
   * Endpoints Merch
   * About Us
   * Help


 * SIGN UP
 * LOG IN




TOP STORIES


FDA'S JANET WOOD­COCK TO RE­TIRE IN EAR­LY 2024

1 hour ago
People
FDA+



BIOTECH’S IPO OUT­LOOK FOR THE REST OF THE YEAR SOURS IN WAKE OF WAR, BROAD­ER
IN­DUS­TRY STRUG­GLES

5 hours ago
Financing
Startups


SLEW OF HOUSE DE­MOC­RATS URGE FDA, HHS TO PRE­SERVE AC­CESS TO MISO­PROS­TOL,
METHOTREX­ATE

1 hour ago
Pharma
FDA+


MU­SIC AGENCY CRE­ATES PAR­O­DY ‘BRAVU­RA’ DRUG AD TO AM­PLI­FY ITS KNACK FOR
PHAR­MA MAR­KET­ING SCORES

50 minutes ago
Pharma
Marketing


LATEST


PA­TIENT FOUN­DA­TION AC­CUS­ES RARE DIS­EASE COM­PA­NY TAYSHA OF VI­O­LAT­ING
LI­CENS­ING AGREE­MENT

1 hour ago
R&D
Cell/Gene Tx


'WELL UN­DER­WAY': FDA CALLS FOR FASTER CON­FIR­MA­TO­RY TRI­ALS FOR
AC­CEL­ER­AT­ED AP­PROVALS

1 hour ago
Pharma
FDA+


KLICK HEALTH AGENCY ADDS AI TEAMS TO AC­CEL­ER­ATE PHAR­MA AND HEALTH­CARE
MAR­KET­ING PROJECTS

2 hours ago
Pharma
Marketing


SAN­DOZ OPENS TWO NEW FA­CIL­I­TIES; GATES FOUN­DA­TION FUNDS NEE­DLE-FREE
VAC­CINES; NO­VAR­TIS EX­PANDS JAPAN­ESE SITE

4 hours ago
Manufacturing


SPRING­WORKS EYES US FIL­ING FOR MEK IN­HIBITOR AF­TER POS­I­TIVE PHI­IB DA­TA
IN RARE DIS­EASE

5 hours ago
R&D


AM­GEN LINES UP NEW AI BIOTECH PART­NER IN POSTERA TO DE­VEL­OP SMALL MOL­E­CULE
MED­I­CINES

6 hours ago
R&D
see latest stream
People


HEARD AT #JEF­FERIES23: AL­NY­LAM, BI­CY­CLE, IN­TEL­LIA, NOUS­COM, RAKUTEN
MED­ICAL EX­ECS FORE­CAST 2024

9 hours ago


THREE MONTHS AF­TER BIG RE­OR­GA­NI­ZA­TION, AN­TI­BODY MAK­ER ATRE­CA IS BACK
WITH AN­OTH­ER ROUND OF LAY­OFFS

Yesterday


THE­SEUS PHAR­MA­CEU­TI­CALS LAYS OFF MOST WORK­ERS AND SEEKS 'S­TRATE­GIC
AL­TER­NA­TIVES' AF­TER CAN­CER PIPELINE FAIL­URE

2 days ago
Financing


SCOOP: RAKUTEN MED­ICAL TAR­GETS YEAR-END CLOSE FOR $100M+ SE­RIES E TO FUND
PHO­TOIM­MUNOTHER­A­PY PIPELINE: #JEF­FERIES23

8 hours ago


SCOOP: CELL­PROTHERA EYES $30M ROUND FOR PHI­II TRI­AL OF CELL THER­A­PY FOR
HEART AT­TACKS: #JEF­FERIES23

Yesterday


NMD PHAR­MA SE­CURES €75M FROM IN­SID­ERS FOR THREE PHII TRI­ALS IN
NEU­RO­MUS­CU­LAR DIS­OR­DERS

Yesterday
Startups


Q32 BIO TO TAKE HO­MOL­O­GY MED­I­CINES’ NAS­DAQ SPOT TO FUND PHII TRI­ALS IN
AU­TOIM­MUNE, IN­FLAM­MA­TO­RY CON­DI­TIONS

7 hours ago


PRI­MA­RY CARE START­UP FOR­WARD RAIS­ES $100M TO GROW NA­TION­AL­LY WITH
SELF-SER­VICE ‘CARE­PODS’

Yesterday


MUR­AL ON­COL­O­GY SPINS OUT FROM ALK­ER­MES WITH $275M AND A LEAD
IM­MUNOTHER­A­PY PRO­GRAM

Yesterday
Deals


ASTEL­LAS BAGS PROSTATE CAN­CER DRUG IN $175M BUY­OUT AS XTAN­DI AP­PROACH­ES
PATENT CLIFF

10 hours ago


IN­VESTORS OR­BIMED AND FORE­SITE SAY THEY'RE LOOK­ING AT TAK­ING KIN­NATE
PRI­VATE, FOL­LOW­ING PIPELINE AND STAFF CUTS

21 hours ago


GRAPHITE BIO HANDS NAS­DAQ SPOT TO PRES­BY­OPIA BIOTECH LENZ THER­A­PEU­TICS AS
PHI­II READ­OUTS LOOM

Yesterday



IN FOCUSSEE ALL


FUL­LY SYN­THET­IC GENOME NEARS COM­PLE­TION IN A STEP TO­WARD UN­RAV­EL­ING
GE­NET­IC MYS­TER­IES

Last week
R&D
Discovery


MR­NA’S NEXT TRICK? RE­PRO­GRAM­MING OFF-THE-SHELF CELL THER­A­PIES FOR CAN­CER
AND AU­TOIM­MUNE DIS­EASES

Last week
Cell/Gene Tx


RA­DIO­PHAR­MA CD­MOS NAV­I­GATE SUP­PLY CHAIN, RAW MA­TE­R­I­AL CHAL­LENGES AS
DE­MAND GOES NU­CLEAR

2 weeks ago
Manufacturing


AF­TER THE AP­PLAUSE: NEW EF­FI­CA­CY EX­PEC­TA­TIONS IN UROTHE­LIAL CAN­CER
AF­TER PAD­CEV-KEYTRU­DA DA­TA RE­VEAL

3 weeks ago
R&D
Pharma


ENDPOINTS STANDOUTS


A CON­VER­SA­TION WITH NO­BEL PRIZE WIN­NER KATAL­IN KARIKÓ ON RE­JEC­TION,
FI­NAL­LY BE­ING REC­OG­NIZED AND HER MR­NA WORK

Last month
People


AF­TER YEARS OF HYPE, THE FIRST AI-DE­SIGNED DRUGS FALL SHORT IN THE CLIN­IC

4 weeks ago
AI
In Focus


HOW NO­VO NORDISK’S RY­BEL­SUS WENT FROM PAN­DEM­IC WASHOUT TO BLOCK­BUSTER, AND
WHAT’S NEXT FOR ORAL WEIGHT LOSS

4 weeks ago
Pharma
Marketing


MOST DE­TAILED HU­MAN BRAIN MAP YET IS ‘LAY­ING THE FOUN­DA­TION FOR FIND­ING
FU­TURE CURES’

Last month
R&D
In Focus


PEER REVIEW SEE ALL

Nov
10


CEN­TU­RY THER­A­PEU­TICS NABS BRIS­TOL MY­ERS ALUM AS CEO; EN­HER­TU STAR
DAI­ICHI SANKYO MAKES CHANGES IN EU­ROPE

Nov
3


CNS BIOTECH RAP­PORT SNAGS A CFO VET­ER­AN FROM KARUNA; BRIS­TOL MY­ERS’ NEW CEO
TO CHAIR THE BOARD NEXT YEAR

Oct
27


FLAG­SHIP'S MON­TAI HEALTH HIRES FIRST CMO; FI­NANCE LEADER TO RE­TIRE AT J&J
PART­NER XEN­COR

Oct
20


CO-FOUND­ED BY DAVID BAK­ER, VILYA RINGS IN A PER­MA­NENT CEO; AL­LO­GENE NAMES
ER­IC SCHMIDT'S CFO SUC­CES­SOR

Oct
13


PO­SEI­DA PRO­MOTES CELL THER­A­PY PRES­I­DENT TO CEO; AF­TER IPO, NEUMO­RA
AP­POINTS R&D CHIEF


PHARMA CHANNEL FEED

8 hours ago


FDA HANDS DOWN AP­PROVAL FOR BRIS­TOL MY­ER­S' LUNG CAN­CER DRUG FROM TURN­ING
POINT BUY­OUT

Bris­tol My­ers Squibb’s $4.1 bil­lion buy­out of Turn­ing Point Ther­a­peu­tics
has paid off, with the FDA hand­ing down an ap­proval of the lead can­cer drug
in the ac­qui­si­tion.

READ MORE


NO­VO NORDISK LAUNCH­ES HEAD-TO-HEAD TRI­AL WITH ELI LIL­LY AS WEIGHT LOSS
RI­VAL­RY HEATS UP

Yesterday


OZEM­PIC SHORT­AGES HAVE EU­RO­PEAN COUN­TRIES EX­PLOR­ING BANS ON USE OF
POP­U­LAR DRUG FOR WEIGHT LOSS

Yesterday
Manufacturing
latest in Pharma


CORMEDIX WINS US AP­PROVAL VIA RARELY-USED PATH­WAY FOR DRUG TO RE­DUCE
BLOOD­STREAM IN­FEC­TIONS

Yesterday
FDA+


A MARK CUBAN COPY? CIGNA’S EX­PRESS SCRIPTS TO OF­FER WHAT IT CALLS AN­OTH­ER
COST-PLUS PRIC­ING MOD­EL

Yesterday
Health Tech


CAN POST-MAR­KET EV­I­DENCE GEN­ER­A­TION BE STREAM­LINED? FDA-COM­MIS­SIONED
RE­PORT PRO­POS­ES SO­LU­TIONS

Yesterday
FDA+


FDA RAIS­ES CON­CERNS OVER EF­FI­CA­CY OF MER­CK­'S PO­TEN­TIAL CHRON­IC COUGH
DRUG AHEAD OF AD­COMM

Yesterday
FDA+


PFIZ­ER TO CUT 500 JOBS AT SAND­WICH, UK SITE

2 days ago
see latest stories


MARKETING CHANNEL FEED

Yesterday


PHAR­MAS AND PHYSI­CIANS VAL­UE MED­ICAL AF­FAIRS AND MSLS, BUT HAVE DIF­FER­ENT
CON­TENT PRI­OR­I­TIES, SUR­VEY SAYS

Phar­ma com­pa­nies and physi­cians agree on the in­creased im­por­tance of
med­ical af­fairs and dig­i­tal com­mu­ni­ca­tions, but still have dif­fer­ent
views on what kind of con­tent is most help­ful.

READ MORE


SANOFI HANDS OUT COM­MU­NI­TY HEALTH EQ­UI­TY GRANTS IN ON­GO­ING EF­FORT TO
BUILD TRUST WITH MAR­GIN­AL­IZED GROUPS

Yesterday
Pharma


ELI LIL­LY WINS PRE­LIM­I­NARY IN­JUNC­TION IN MOUN­JARO CASE IN DRUG­MAK­ER­S'
ON­GO­ING BAT­TLE WITH COM­POUND­ING PHAR­MA­CIES, ...

Yesterday
Pharma
Law
latest in Marketing


HOW VI­RAL TIK­TOK TRENDS ARE CATCH­ING ON IN PHAR­MA MAR­KET­ING

2 days ago


NO­VAR­TIS ADDS TO MUL­TI­PLE SCLE­RO­SIS 'LOVE STO­RY' CAM­PAIGN WITH MORE
PA­TIENT PER­SPEC­TIVES

2 days ago
Pharma


MAR­KET­INGRX ROUNDUP: VI­A­TRIS DE­BUTS NEW CAM­PAIGN IN TIMES SQUARE;
AS­TRAZENECA RE­NEWS NAT­UR­AL GAS DEAL

2 days ago
Pharma


GSK RAIS­ES RARE BLOOD CAN­CER AWARE­NESS WITH WELL-KNOWN ‘QUEER EYE’ DE­SIGN­ER

3 days ago
Pharma


GILEAD SPOT­LIGHTS ITS ON­COL­O­GY WORK WITH FIRST FO­CUSED BRAND­ING CAM­PAIGN

6 days ago
Pharma
see latest stories


FDA+ CHANNEL FEED

9 hours ago


IN A WORLD FIRST, VER­TEX, CRISPR WIN UK AP­PROVAL FOR CRISPR-EDIT­ED THER­A­PY
TO TREAT SICK­LE CELL DIS­EASE, BE­TA-THA­LASSEMIA

Ver­tex and CRISPR Ther­a­peu­tics have won the first-ever ap­proval for a
ther­a­py cre­at­ed with CRISPR gene edit­ing, as the UK drug reg­u­la­tor MHRA
green­lights their treat­ment for two blood ...

READ MORE


AMA­ZON LANDS FDA WARN­ING LET­TER OVER DIS­TRI­B­U­TION OF SEV­EN UN­AP­PROVED
EYE DROPS

2 days ago


NEW NIH CHIEF STRESS­ES FO­CUS ON OBE­SI­TY, CLIN­I­CAL TRI­AL CHAL­LENGES

2 days ago
Pharma
latest in FDA+


FDA TOUTS NEW AU­THOR­I­TY AS ODAC HOSTS AD­COMM TO RE­VIEW DE­LAYED
CON­FIR­MA­TO­RY TRI­ALS FOR AC­CEL­ER­AT­ED AP­PROVALS

2 days ago


JAPAN CON­SID­ERS AD­JUST­ING CLIN­I­CAL TRI­AL RE­QUIRE­MENTS TO RE­MOVE THE
NEED FOR LO­CAL STUD­IES — RE­PORT

3 days ago
Pharma


FDA EX­PLAINS WHY IT DE­NIED ABOUT 60% OF NON-ON­COL­O­GY BREAK­THROUGH
THER­A­PY RE­QUESTS FROM 2017 TO 2019

3 days ago
Pharma


EMA COM­MIT­TEE REC­OM­MENDS AP­PROVALS FOR LIL­LY'S WEIGHT LOSS DRUG, MI­RATI'S
KRAS IN­HIBITOR AND MORE

6 days ago
Pharma


HOUSE RE­PUB­LI­CANS THREAT­EN TO SUB­POE­NA FDA OVER COVID RE­SEARCH
DOC­U­MENTS

6 days ago
Pharma
see latest stories


MANUFACTURING CHANNEL FEED

Yesterday


IS THE WORST OVER? CATAL­ENT TOUTS GLP-1 AND GENE THER­A­PY BUSI­NESS AS IT
STICKS TO FI­NAN­CIAL GUID­ANCE

Catal­ent’s fi­nan­cial health ap­pears to be on the mend thanks to spe­cif­ic
seg­ments of its man­u­fac­tur­ing busi­ness, but the CD­MO still has a long
road to re­cov­ery.

READ MORE


EX­CLU­SIVE: NTX RAIS­ES $47.5M SE­RIES B TO COM­MER­CIAL­IZE PRO­TEIN, MR­NA
MAN­U­FAC­TUR­ING PLAT­FORMS 

Yesterday


AJI­NOMO­TO TO BUY GENE THER­A­PY CD­MO FORGE BI­O­LOG­ICS IN $620M ALL-CASH
DEAL

3 days ago
Deals
latest in Manufacturing


THER­MO FISH­ER PLANS TO LAY OFF 97 EM­PLOY­EES, CLOSE FA­CIL­I­TY IN AL­ABA­MA

6 days ago
People


NO­VO IN­VESTS $6B+ TO EX­PAND MAN­U­FAC­TUR­ING FA­CIL­I­TIES AS DE­MAND FOR
WE­GOVY SKY­ROCK­ETS

6 days ago
Pharma
Cell/Gene Tx


CAM­BREX SELLS DRUG PROD­UCT BUSI­NESS; LAND­MARK TO WORK WITH GALA­PA­GOS;
GENEZEN LOCKS $18.5M EQ­UI­TY BOOST 

Last week


COM­MER­CIAL-STAGE MAN­U­FAC­TUR­ING KEY FOR CD­MOS AS BIOTECH FUND­ING
PULL­BACK CON­TIN­UES, FU­JI­FILM DIOSYNTH CEO SAYS

Last week


CHARLES RIV­ER’S CD­MO BUSI­NESS SLOWS; LIL­LY BOOSTS GLP-1 CA­PAC­I­TY; TE­VA’S
IS­RAEL SITES 'U­NAF­FECT­ED'

Last week
see latest stories

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas




LATEST

 * All News
 * Special
 * In Focus
   


CHANNELS

 * AI
 * Bioregnum
 * Biotech Voices
 * Cell/Gene Tx
 * China
 * Coronavirus
 * Deals
 * Diagnostics
 * Discovery
 * FDA+
 * Financing
 * Health Tech
 * Law
 * Letters to the Editor
 * Manufacturing
 * Marketing
 * Opinion
 * Outsourcing
 * Peer Review
 * People
 * Pharma
 * R&D
 * Startups
 * Weekly


MORE

 * Work at Endpoints
 * Letter to Editors
 * IPO Tracker
 * Events
 * Webinars
 * Sponsored Posts
 * Advertise
 * Endpoints Merch
 * About Us
 * Help


WORK IN BIOTECH

 * Endpoints Careers

© Endpoints News 2023

 * Help
 * Advertise
 * Privacy Policy
 * Business Model




LOG IN TO YOUR ACCOUNT


EMAIL




PASSWORD


Change my password Get a magic email link
LOG IN


REQUEST MAGIC LINK

If you're already an Endpoints subscriber, enter your email below for a magic
link that lets you log in quickly without using a password. Please note the
magic link is one-time use only and expires after 24 hours.


EMAIL


BACK
REQUEST


RESET PASSWORD

We'll e-mail you a link to set a new password. Please note this link is one-time
use only and is valid for only 24 hours.


EMAIL


BACK
RESET

SIGN UP FOR FREE TO READ A LIMITED NUMBER OF ARTICLES EACH MONTH.

ABOUT YOU







NEWSLETTER INTERESTS

PICK WHAT NEWSLETTERS GET DELIVERED TO YOUR INBOX EACH WEEK.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET



EARLY EDITION Daily at 7:15 AM ET



ENDPOINTS PHARMA Daily at 2 PM ET



BREAKING NEWS ALERTS 2-3 times a week



ENDPOINTS MARKETING RX Tue at 2 PM ET



ENDPOINTS FDA+ Wed at 2 PM ET



ENDPOINTS MANUFACTURING Thu at 2 PM ET



ENDPOINTS WEEKLY Sat at 6 AM ET



Healthcare

ENDPOINTS HEALTH TECH Coming soon


INSTANT SIGN UP

Want unlimited access? Sign up for a premium subscription plan.